157 related articles for article (PubMed ID: 18177513)
1. The PPARgamma ligand rosiglitazone influences triacylglycerol metabolism in non-obese males, without increasing the transcriptional activity of PPARgamma in the subcutaneous adipose tissue.
Joosen AM; Bakker AH; Kersten S; Westerterp KR
Br J Nutr; 2008 Mar; 99(3):487-93. PubMed ID: 18177513
[TBL] [Abstract][Full Text] [Related]
2. The effect of the PPARgamma ligand rosiglitazone on energy balance regulation.
Joosen AM; Bakker AH; Gering MJ; Westerterp KR
Diabetes Metab Res Rev; 2006; 22(3):204-10. PubMed ID: 16110522
[TBL] [Abstract][Full Text] [Related]
3. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
Berthiaume M; Laplante M; Tchernof A; Deshaies Y
Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.
Walker GE; Marzullo P; Verti B; Guzzaloni G; Maestrini S; Zurleni F; Liuzzi A; Di Blasio AM
Obesity (Silver Spring); 2008 Sep; 16(9):1983-91. PubMed ID: 19186324
[TBL] [Abstract][Full Text] [Related]
5. Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression.
Moore GB; Pickavance LC; Briscoe CP; Clapham JC; Buckingham RE; Wilding JP
Diabetes Obes Metab; 2008 Mar; 10(3):251-63. PubMed ID: 18269641
[TBL] [Abstract][Full Text] [Related]
6. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
[TBL] [Abstract][Full Text] [Related]
7. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
Törüner F; Akbay E; Cakir N; Sancak B; Elbeg S; Taneri F; Aktürk M; Karakoç A; Ayvaz G; Arslan M
Horm Metab Res; 2004 Apr; 36(4):226-30. PubMed ID: 15114521
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.
Nakano R; Kurosaki E; Yoshida S; Yokono M; Shimaya A; Maruyama T; Shibasaki M
Biochem Pharmacol; 2006 Jun; 72(1):42-52. PubMed ID: 16696951
[TBL] [Abstract][Full Text] [Related]
9. Prolonged decrease of adipocyte size after rosiglitazone treatment in high- and low-fat-fed rats.
Johnson JA; Trasino SE; Ferrante AW; Vasselli JR
Obesity (Silver Spring); 2007 Nov; 15(11):2653-63. PubMed ID: 18070756
[TBL] [Abstract][Full Text] [Related]
10. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
11. Effect of fasting on PPARgamma and AMPK activity in adipocytes.
Kajita K; Mune T; Ikeda T; Matsumoto M; Uno Y; Sugiyama C; Matsubara K; Morita H; Takemura M; Seishima M; Takeda J; Ishizuka T
Diabetes Res Clin Pract; 2008 Aug; 81(2):144-9. PubMed ID: 18562038
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.
Hwang YC; Lee EY; Lee WJ; Cha BS; Yoon KH; Park KS; Lee MK
Metabolism; 2008 Apr; 57(4):479-87. PubMed ID: 18328348
[TBL] [Abstract][Full Text] [Related]
13. Short term 13-cis-retinoic acid treatment at therapeutic doses elevates expression of leptin, GLUT4, PPARgamma and aP2 in rat adipose tissue.
Krskova-Tybitanclova K; Macejova D; Brtko J; Baculikova M; Krizanova O; Zorad S
J Physiol Pharmacol; 2008 Dec; 59(4):731-43. PubMed ID: 19212007
[TBL] [Abstract][Full Text] [Related]
14. The effects of thiazolidinedione treatment on the regulations of aquaglyceroporins and glycerol kinase in OLETF rats.
Lee DH; Park DB; Lee YK; An CS; Oh YS; Kang JS; Kang SH; Chung MY
Metabolism; 2005 Oct; 54(10):1282-9. PubMed ID: 16154425
[TBL] [Abstract][Full Text] [Related]
15. Flaxseed lignan attenuates high-fat diet-induced fat accumulation and induces adiponectin expression in mice.
Fukumitsu S; Aida K; Ueno N; Ozawa S; Takahashi Y; Kobori M
Br J Nutr; 2008 Sep; 100(3):669-76. PubMed ID: 18252024
[TBL] [Abstract][Full Text] [Related]
16. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF
Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099
[TBL] [Abstract][Full Text] [Related]
17. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.
Li W; Tonelli J; Kishore P; Owen R; Goodman E; Scherer PE; Hawkins M
Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1301-7. PubMed ID: 17213476
[TBL] [Abstract][Full Text] [Related]
18. [Healthy persons versus patients with diabetes mellitus type 2--choosen parameters in serum and subcutaneous abdominal adipose tissue].
Ben Yahia R; Lichnovská R; Janusová L; Kuzmina G; Karpísek M; Kollár P; Petrek J
Vnitr Lek; 2007 Jan; 53(1):9, 11-7. PubMed ID: 17472010
[TBL] [Abstract][Full Text] [Related]
19. Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte.
Wang X; Wang Z; Liu JZ; Hu JX; Chen HL; Li WL; Hai CX
Toxicol In Vitro; 2011 Jun; 25(4):839-47. PubMed ID: 21333731
[TBL] [Abstract][Full Text] [Related]
20. Norepinephrine and rosiglitazone synergistically induce Elovl3 expression in brown adipocytes.
Jörgensen JA; Zadravec D; Jacobsson A
Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1159-68. PubMed ID: 17726147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
